Cyclosporine in Relapsed Subcutaneous Panniculitis-like T-Cell Lymphoma after Autologous Hematopoietic Stem Cell Transplantation.
- Author:
Hye Ryun JUNG
1
;
So Yeon YUN
;
Jun Hyeok CHOI
;
Sung Hwa BAE
;
Hun Mo RYOO
;
Yoon Seup KUM
Author Information
1. Division of Hematology/Oncology, Department of Internal Medicine, Daegu Catholic University Hospital, Catholic University of Daegu School of Medicine, Daegu, Korea. sunghwa@cu.ac.kr
- Publication Type:Case Report
- Keywords:
Panniculitis;
Lymphoma;
T-lymphocytes;
Cyclosporine
- MeSH:
Cyclophosphamide;
Cyclosporine;
Doxorubicin;
Hematopoietic Stem Cell Transplantation;
Hematopoietic Stem Cells;
Humans;
Lymphohistiocytosis, Hemophagocytic;
Lymphoma;
Lymphoma, T-Cell;
Panniculitis;
Prednisolone;
Stress, Psychological;
Subcutaneous Tissue;
T-Lymphocytes;
Vincristine
- From:Cancer Research and Treatment
2011;43(4):255-259
- CountryRepublic of Korea
- Language:English
-
Abstract:
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare T-cell lymphoma characterized by involvement of the subcutaneous tissue of neoplastic T lymphocytes. SPTCL with hemophagocytic syndrome (HPS) is associated with an aggressive clinical course and treatment of SPTCL with HPS is not well established. Cyclophosphamide, doxorubicin, vincristine, prednisolone (CHOP) therapy is not successful in most patients suffering from SPTCL with HPS. The role of high dose chemotherapy followed by hematopoietic stem cell transplantation (HSCT) remains controversial. We report a case of relapsed SPTCL after CHOP chemotherapy and salvage chemotherapy followed by autologous HSCT, which had rapid improvement within weeks after cyclosporine and prednisolone. Immunosuppressive therapy may be an important and successful treatment option in SPTCL patients, even though they may have clinically aggressive disease.
